Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Allon Therapeutics Inc NPCUF

Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and other conditions involving neurodegeneration. The Company's drug, davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).


GREY:NPCUF - Post by User

Bullboard Posts
Comment by your_solution1on Dec 18, 2012 9:56pm
271 Views
Post# 20748625

RE: RE: RE: Press releases

RE: RE: RE: Press releases

Long time ago I worked as audtior for a company... sometime I found wrong things just by relax and plausible thinking through the whole story .....

- all of the presentations and information seemed to point to a full success of dunavetide

- question:"why was there no insider action buying or selling" during the final weeks before the final announcement?

- was there never a conversation between the scientists and the clinics telling them how the test's are progressing? (normally scientists and clinics keep informing and updating)

impression? if the NPC management was not buying in the last months they probably had information that the drug will fail (most likely insiders will know if it is a success and would acquire more shares)

I remember still the conversation of the CEO with seekingalpha, it left the impression that the clinical tests point to total success...did the CEO already know about the possible results?

https://seekingalpha.com/article/902931-straight-talk-from-allon-therapeutics-ceo-gordon-mccauley

now everybody can make the own analysis. This were just my thoughts

Bullboard Posts